rs879254346
Positions:
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PP3_ModerateBS1_SupportingBS2
The NM_002047.4(GARS1):c.2042C>T(p.Pro681Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000161 in 1,614,028 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000016 ( 0 hom. )
Consequence
GARS1
NM_002047.4 missense
NM_002047.4 missense
Scores
9
8
1
Clinical Significance
Conservation
PhyloP100: 7.88
Genes affected
GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -3 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.843
BS1
Variant frequency is greater than expected in population nfe. gnomad4_exome allele frequency = 0.0000164 (24/1461876) while in subpopulation NFE AF= 0.0000216 (24/1111998). AF 95% confidence interval is 0.0000146. There are 0 homozygotes in gnomad4_exome. There are 11 alleles in male gnomad4_exome subpopulation. Median coverage is 31. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High AC in GnomAdExome4 at 24 AD gene.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GARS1 | ENST00000389266.8 | c.2042C>T | p.Pro681Leu | missense_variant | 16/17 | 1 | NM_002047.4 | ENSP00000373918.3 | ||
GARS1 | ENST00000675651.1 | c.2060C>T | p.Pro687Leu | missense_variant | 16/17 | ENSP00000502513.1 | ||||
GARS1 | ENST00000675810.1 | c.1940C>T | p.Pro647Leu | missense_variant | 15/16 | ENSP00000502743.1 | ||||
GARS1 | ENST00000675693.1 | c.1874C>T | p.Pro625Leu | missense_variant | 17/18 | ENSP00000502174.1 | ||||
GARS1 | ENST00000675051.1 | c.1841C>T | p.Pro614Leu | missense_variant | 16/17 | ENSP00000502296.1 | ||||
GARS1 | ENST00000674815.1 | c.1673C>T | p.Pro558Leu | missense_variant | 16/17 | ENSP00000502799.1 | ||||
GARS1 | ENST00000674851.1 | c.1673C>T | p.Pro558Leu | missense_variant | 17/18 | ENSP00000502451.1 | ||||
GARS1 | ENST00000444666.6 | n.*463C>T | non_coding_transcript_exon_variant | 17/18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.*1756C>T | non_coding_transcript_exon_variant | 17/18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*1847C>T | non_coding_transcript_exon_variant | 16/17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*1380C>T | non_coding_transcript_exon_variant | 17/18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000674807.1 | n.*315C>T | non_coding_transcript_exon_variant | 15/16 | ENSP00000502814.1 | |||||
GARS1 | ENST00000675529.1 | n.*1912C>T | non_coding_transcript_exon_variant | 17/18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000675859.1 | n.*221C>T | non_coding_transcript_exon_variant | 14/15 | ENSP00000502033.1 | |||||
GARS1 | ENST00000676088.1 | n.*1984C>T | non_coding_transcript_exon_variant | 18/19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*987C>T | non_coding_transcript_exon_variant | 16/17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*1493C>T | non_coding_transcript_exon_variant | 16/17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*1331C>T | non_coding_transcript_exon_variant | 17/18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*1474C>T | non_coding_transcript_exon_variant | 16/17 | ENSP00000501980.1 | |||||
GARS1 | ENST00000676403.1 | n.*127C>T | non_coding_transcript_exon_variant | 15/16 | ENSP00000502681.1 | |||||
GARS1 | ENST00000444666.6 | n.*463C>T | 3_prime_UTR_variant | 17/18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.*1756C>T | 3_prime_UTR_variant | 17/18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*1847C>T | 3_prime_UTR_variant | 16/17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*1380C>T | 3_prime_UTR_variant | 17/18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000674807.1 | n.*315C>T | 3_prime_UTR_variant | 15/16 | ENSP00000502814.1 | |||||
GARS1 | ENST00000675529.1 | n.*1912C>T | 3_prime_UTR_variant | 17/18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000675859.1 | n.*221C>T | 3_prime_UTR_variant | 14/15 | ENSP00000502033.1 | |||||
GARS1 | ENST00000676088.1 | n.*1984C>T | 3_prime_UTR_variant | 18/19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*987C>T | 3_prime_UTR_variant | 16/17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*1493C>T | 3_prime_UTR_variant | 16/17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*1331C>T | 3_prime_UTR_variant | 17/18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*1474C>T | 3_prime_UTR_variant | 16/17 | ENSP00000501980.1 | |||||
GARS1 | ENST00000676403.1 | n.*127C>T | 3_prime_UTR_variant | 15/16 | ENSP00000502681.1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152152Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152152
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000401 AC: 1AN: 249562Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135394
GnomAD3 exomes
AF:
AC:
1
AN:
249562
Hom.:
AF XY:
AC XY:
0
AN XY:
135394
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1461876Hom.: 0 Cov.: 31 AF XY: 0.0000151 AC XY: 11AN XY: 727242
GnomAD4 exome
AF:
AC:
24
AN:
1461876
Hom.:
Cov.:
31
AF XY:
AC XY:
11
AN XY:
727242
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152152Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74316
GnomAD4 genome
AF:
AC:
2
AN:
152152
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74316
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 24, 2022 | The p.P681L variant (also known as c.2042C>T), located in coding exon 16 of the GARS gene, results from a C to T substitution at nucleotide position 2042. The proline at codon 681 is replaced by leucine, an amino acid with similar properties. This variant was identified in one allele in a Charcot-Marie Tooth cohort (Volodarsky M et al. J Med Genet, 2021 04;58:284-288). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Charcot-Marie-Tooth disease type 2D;CN031873:Neuronopathy, distal hereditary motor, type 5A Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 11, 2017 | - - |
Charcot-Marie-Tooth disease type 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 27, 2023 | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 681 of the GARS protein (p.Pro681Leu). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This missense change has been observed in individual(s) with clinical features of Charcot-Marie-Tooth disease (PMID: 32376792). ClinVar contains an entry for this variant (Variation ID: 246654). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on GARS protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 09, 2024 | Reported in a patient with a suspected diagnosis of Charcot-Marie-Tooth disease; however, no further clinical or segregation information was provided (PMID: 32376792); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32376792) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
D
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
D
Vest4
MutPred
Loss of disorder (P = 0.0477);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at